Alexander Perl is an Oncology physician affiliated with Abramson Cancer Center. OpenAlex indexes 416 publications with 16,545 citations (h-index 56); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104
Telephone
215-662-3914Registry record last updated 19 Aug 2013.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year202516 payments$14,046openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year20257 payments$12,513openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Europe GmbHProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
- mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2014$172,368K23CA141054 - mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2013$172,368K23CA141054 - mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2012$172,368K23CA141054
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024 - Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ben Stanger, MD
Abramson Cancer Center
David Mankoff, MD, PhD
Abramson Cancer Center
Michael Soulen, MD
Abramson Cancer Center
Alison Loren, MD
Abramson Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”